in pictures and a few words
What it is and why it matters
Setmelanotide is a prescription injection given once a day. It is used for rare forms of severe obesity in which the fullness signal itself is broken.
- The main trouble in these forms is hunger that does not go away after eating
- It is not about overeating or willpower: fullness simply does not come
- It is not a weight-loss drug but a fix for one specific breakdown
How it works
The brain has a chain that reports: there is enough energy, you can stop eating. In these diseases one link is broken, and the brain switches on hunger.
- The drug sends the fullness signal itself, bypassing the broken link
- Hunger eases, the person eats less, and energy use partly rises
Who it is for
Only three groups. It is not used for common obesity, including obesity with type 2 diabetes: if the fullness signal works, there is nothing to switch on.
- After a tumor, surgery or injury to the brain area that controls hunger — from age 4
- Bardet-Biedl syndrome, a rare inborn disease — from age 2
- A breakdown in one of three genes of this chain, confirmed by testing — from age 2
What was shown in people
The drug was tested in all three forms. Weight went down, and in the inborn forms the tormenting hunger lessened as well.
- After brain damage, weight relative to height clearly fell; with a dummy drug it did not
- Bardet-Biedl syndrome: weight went down, hunger became weaker
- Gene breakdown: in a large share of people weight clearly fell, hunger eased
Tested in people. Tested in people. For the person and the family, the burden of the disease is more often set by the hunger, not the number on the scale.
A long-term treatment
The effect lasts as long as the injections continue. After stopping, weight usually comes back: the cause remains, and the drug only replaces the missing signal.
- It is not a course but long-term treatment
- Discuss this with your doctor before starting, not after the first results
How it is given
An injection under the skin once a day, usually in the morning. It goes into the belly, thigh or upper arm, changing the spot each time.
- Start with a small dose and raise it if it is well tolerated
- The doctor chooses the dose — it depends on the disease and age
- The person or the parents are taught to give the injections
Skin may darken
The drug also slightly switches on a neighboring receptor that controls skin color. That is why most people’s skin darkens, and moles may darken too.
- This is an expected effect, not a complication
- By itself it is not dangerous and goes away after stopping
- The change in looks is noticeable — better to know about it in advance
What else can happen
Common ones are injection-site reactions, nausea, vomiting, diarrhea, belly pain and headache.
- In men — erections without arousal, in women — changes in arousal
- Allergy is possible — as with any injection
Important. An erection lasting longer than 4 hours is an emergency: urgent medical help is needed.
Who should see a doctor first
The drug is prescription-only: a doctor prescribes and monitors it. First the diagnosis is confirmed by a genetic test or by evidence of brain damage.
- Kidney disease — the dose may be changed; at the last stage the drug is not recommended
- Newborns and babies — it contains benzyl alcohol
- Depression is common — mood is watched throughout treatment
Important. Mood is checked throughout treatment, especially in teenagers: low mood and thoughts of suicide need a doctor’s attention.
In one sentence
In three rare forms of obesity with a broken fullness signal, setmelanotide eases hunger and lowers weight while it is being injected; it is not used for common obesity.
In brief
Indications
| Condition | From age | Requirement |
|---|---|---|
| Acquired hypothalamic obesity — after a tumour, surgery or injury of the hypothalamus | 4 | First approved targeted therapy for the condition; label expanded in 2026 |
| Bardet-Biedl syndrome | 2 | — |
| Obesity due to POMC, PCSK1 or LEPR deficiency | 2 | Genetic confirmation mandatory (pathogenic, likely pathogenic or variants of uncertain significance) |
All three groups share hyperphagia: not a habit of eating a lot, but insatiable hunger in which satiety never physiologically forms. That, rather than the number on the scale, usually defines the severity for patient and family.
Mechanism
The hypothalamus runs a chain that tells the brain energy is sufficient: leptin from adipose tissue → POMC neurons → production of α-melanocyte-stimulating hormone (α-MSH) → activation of MC4R → satiety and normal energy expenditure.
In POMC or PCSK1 deficiency the signalling peptide is never made; in LEPR deficiency leptin is not sensed; after hypothalamic damage the neurons serving the chain are destroyed. The result is identical: MC4R receives no signal, the brain concludes energy is short, and hunger switches on.
Setmelanotide is a synthetic α-MSH analogue. It activates the receptor directly, bypassing the broken link. Hunger falls, calorie intake drops and energy expenditure rises somewhat.
The mechanism carries a built-in consequence: the drug also weakly activates the related MC1R receptor, which governs skin pigmentation. Hence skin darkening — an expected effect rather than a complication.
Dosing and administration
▸subcutaneous, once daily, usually in the morning; ▸sites — abdomen, thigh or upper arm, rotated; ▸supplied as a 10 mg/mL solution in a multiple-dose vial; ▸the dose is titrated: start low, increase as tolerated.
| Indication and age | Starting dose | Maintenance |
|---|---|---|
| Hypothalamic obesity, from age 4 | 0.5 mg/day | up to 3 mg/day (weight-based under age 6) |
| Bardet-Biedl, POMC/PCSK1/LEPR — adults and from age 12 | 2 mg/day | up to 3 mg/day |
| Same indications, children 6–12 | 1 mg/day | as tolerated |
| Same indications, children 2–6 | 0.5 mg/day | as tolerated |
What the trials showed
▸Acquired hypothalamic obesity. In the phase 3 TRANSCEND trial published in the New England Journal of Medicine in 2026, BMI fell by roughly 15–16% over 52 weeks, with no reduction on placebo [1]. ▸Bardet-Biedl syndrome. A phase 3 trial confirmed weight reduction and reduced hyperphagia [2]. ▸POMC and LEPR deficiency. In phase 3 trials a substantial proportion of patients achieved clinically meaningful weight loss, with separately documented reductions in hunger [3].
Adverse effects
Common (20% or more in one or more groups):
▸skin and mole darkening — a consequence of MC1R activation; ▸injection-site reactions; ▸nausea, vomiting, diarrhoea, abdominal pain; ▸headache; ▸in men, spontaneous erections without sexual stimulation; in women, changes in arousal; ▸depression — requires active monitoring throughout treatment.
Requiring particular attention:
| Issue | Why it matters |
|---|---|
| Priapism — an erection lasting over 4 hours | A medical emergency requiring urgent care |
| Mood disturbance, suicidal thoughts | Mental-health monitoring is mandatory, particularly in adolescents |
| Allergic reactions | Standard vigilance for an injectable product |
| Benzyl alcohol in the formulation | Relevant in neonates and very young children |
What to understand before starting
▸This is treatment for a rare disease, not a weight-loss aid. The diagnosis must be confirmed: genetic testing where POMC, PCSK1 or LEPR deficiency is suspected, documented hypothalamic damage in the acquired form. ▸Therapy is long-term. Stopping returns the weight. ▸Skin will darken. Expected, reversible and not dangerous — but it is fairer to agree on it in advance. ▸Mood must be monitored. Depression sits among the common effects, and the patient population is largely children and adolescents. ▸It is prescription-only, prescribed and supervised by a clinician, and injections require training for the patient or parents.
Indications and eligibility can be discussed at a consultation; the product can be ordered here and is dispensed on prescription.
References
1. Miller JL, et al. Setmelanotide for the treatment of acquired hypothalamic obesity. N Engl J Med. 2026. PMID 42418774
2. Haqq AM, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(12):859–868. PMID 36356613
3. Clément K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–970. PMID 33137293
4. Argente J, et al. Setmelanotide in Bardet-Biedl syndrome: a 52-week comparison of phase 3 trial participants. Obesity (Silver Spring). 2026. PMID 41703984
5. IMCIVREE (setmelanotide) US Prescribing Information, Rhythm Pharmaceuticals.
Key facts
- Setmelanotide (brand name Imcivree, Rhythm Pharmaceuticals) is a synthetic analogue of α-melanocyte-stimulating hormone and a selective agonist of the melanocortin-4 receptor (MC4R). It does not "suppress appetite" in general terms — it restores signalling in one specific broken pathway.
- The indications are strictly limited: acquired hypothalamic obesity (from age 4), Bardet-Biedl syndrome (from age 2) and obesity due to genetically confirmed POMC, PCSK1 or LEPR deficiency (from age 2). Genetic testing is mandatory for the last group.
- It is not used in common obesity: if the MC4R pathway is intact, there is nothing to switch on. This is the fundamental difference from GLP-1 receptor agonists.
- Acquired hypothalamic obesity follows a tumour, surgery or injury involving the hypothalamus. Setmelanotide became the first approved targeted therapy for it, with the label expanded in 2026.
- The mechanism in one line: in POMC, PCSK1 or LEPR deficiency, or after hypothalamic damage, the MC4R receptor never receives the satiety signal, producing hyperphagia; the drug activates the receptor directly, bypassing the broken link.
- One adverse effect is built into the mechanism: setmelanotide weakly activates MC1R, the pigmentation receptor, so skin darkening occurs in most patients. It is expected rather than a complication.
- Administration is subcutaneous once daily, usually in the morning, into the abdomen, thigh or upper arm with site rotation. Supplied as a 10 mg/mL solution in a multiple-dose vial.
- Dosing is titrated and depends on indication and age: hypothalamic obesity starts at 0.5 mg/day rising to a maintenance 3 mg/day; in Bardet-Biedl syndrome and the genetic deficiencies, adults and adolescents start at 2 mg/day rising to 3 mg/day, children aged 6–12 start at 1 mg and children aged 2–6 at 0.5 mg.
- Efficacy: in acquired hypothalamic obesity a phase 3 trial showed a BMI reduction of roughly 15–16% over 52 weeks versus no reduction on placebo; in the genetic forms, substantial weight loss and — no less important — a reduction in hyperphagia.
- The effect lasts while treatment continues: after withdrawal weight generally returns. This is long-term therapy, not a course.
